These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

598 related items for PubMed ID: 19493471

  • 1. In vitro anticoagulation monitoring of low-molecular-weight heparin.
    Wang JQ, Shi XB, Yang JG, Hu DY.
    Chin Med J (Engl); 2009 May 20; 122(10):1199-202. PubMed ID: 19493471
    [Abstract] [Full Text] [Related]

  • 2. Effects of low molecular weight heparin on clot rate and activated clotting time: an in vitro study.
    Shi XB, Bai Y, Li J, Xiao J, Wang JQ, Zheng H.
    Chin Med J (Engl); 2013 May 20; 126(18):3553-6. PubMed ID: 24034107
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. A novel point-of-care assay for the monitoring of low-molecular weight heparins in the cardiac catheterization laboratory.
    Marmur JD, Lakhani M, El Rouby S, Cavusoglu E.
    J Invasive Cardiol; 2008 Sep 20; 20(9):449-54. PubMed ID: 18762674
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Are activated clotting times helpful in the management of anticoagulation with subcutaneous low-molecular-weight heparin?
    Henry TD, Satran D, Knox LL, Iacarella CL, Laxson DD, Antman EM.
    Am Heart J; 2001 Oct 20; 142(4):590-3. PubMed ID: 11579347
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Anticoagulative effects of the inhaled low molecular weight heparin certoparin in healthy subjects.
    Scheuch G, Brand P, Meyer T, Herpich C, Müllinger B, Brom J, Weidinger G, Kohlhäufl M, Häussinger K, Spannagl M, Schramm W, Siekmeier R.
    J Physiol Pharmacol; 2007 Nov 20; 58 Suppl 5(Pt 2):603-14. PubMed ID: 18204174
    [Abstract] [Full Text] [Related]

  • 12. [Sensitivity of new reagents for laboratory monitoring of low molecular weight heparin: an in vitro study].
    Shi XB, Wang JQ, Wang JY, Hou XX, Ma ZM.
    Zhonghua Yi Xue Za Zhi; 2011 Jun 14; 91(22):1566-8. PubMed ID: 21914372
    [Abstract] [Full Text] [Related]

  • 13. Aging and venous thromboembolism influence the pharmacodynamics of the anti-factor Xa and anti-thrombin activities of a low molecular weight heparin (nadroparin).
    Mismetti P, Laporte-Simitsidis S, Navarro C, Sié P, d'Azemar P, Necciari J, Duret JP, Gaud C, Decousus H, Boneu B.
    Thromb Haemost; 1998 Jun 14; 79(6):1162-5. PubMed ID: 9657442
    [Abstract] [Full Text] [Related]

  • 14. Comparison of low molecular weight heparins and unfractionated heparin after successive subcutaneous administration. A randomized controlled study in healthy volunteers.
    Pindur G, Heiden M, Köhler M.
    Arzneimittelforschung; 1993 May 14; 43(5):542-7. PubMed ID: 8392345
    [Abstract] [Full Text] [Related]

  • 15. Production method affects the pharmacokinetic and ex vivo biological properties of low molecular weight heparins.
    Brieger D, Dawes J.
    Thromb Haemost; 1997 Feb 14; 77(2):317-22. PubMed ID: 9157589
    [Abstract] [Full Text] [Related]

  • 16. Adding intravenous unfractionated heparin to standard enoxaparin causes excessive anticoagulation not detected by activated clotting time: results of the STACK-on to ENOXaparin (STACKENOX) study.
    Drouet L, Bal dit Sollier C, Martin J.
    Am Heart J; 2009 Aug 14; 158(2):177-84. PubMed ID: 19619692
    [Abstract] [Full Text] [Related]

  • 17. Effects of heparin, haemodilution and aprotinin on kaolin-based activated clotting time: in vitro comparison of two different point of care devices.
    Dalbert S, Ganter MT, Furrer L, Klaghofer R, Zollinger A, Hofer CK.
    Acta Anaesthesiol Scand; 2006 Apr 14; 50(4):461-8. PubMed ID: 16548858
    [Abstract] [Full Text] [Related]

  • 18. Comparison of the effects of low-molecular-weight and unfractioned heparin in horses.
    Monreal L, Villatoro AJ, Monreal M, Espada Y, Anglés AM, Ruiz-Gopegui R.
    Am J Vet Res; 1995 Oct 14; 56(10):1281-5. PubMed ID: 8928943
    [Abstract] [Full Text] [Related]

  • 19. Platelet function monitoring with the Sonoclot analyzer after in vitro tirofiban and heparin administration.
    Tucci MA, Ganter MT, Hamiel CR, Klaghofer R, Zollinger A, Hofer CK.
    J Thorac Cardiovasc Surg; 2006 Jun 14; 131(6):1314-22. PubMed ID: 16733164
    [Abstract] [Full Text] [Related]

  • 20. Changing trends in anti-coagulant therapies. Are heparins and oral anti-coagulants challenged?
    Fareed J, Iqbal O, Cunanan J, Demir M, Wahi R, Clarke M, Adiguzel C, Bick R.
    Int Angiol; 2008 Jun 14; 27(3):176-92. PubMed ID: 18506123
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.